AbbVie gets the FTC's divided blessing for its $63B Allergan buyout — freeing Brent Saunders to blaze a new path
It may have taken a little longer than expected, or seemed like an artifact from the pre-pandemic era. However, AbbVie got the FTC’s OK to complete its mega $63 billion buyout of Allergan Tuesday evening.
The decision followed a familiar path at the FTC, breaking along party lines as Republicans lined up behind a plan to force some drug divestitures — a route that drew a scathing rebuke from Rohit Chopra, the Democrats’ representative who was backed by Rebecca Kelly Slaughter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.